BioPharmSignal logoBioPharmSignal

Biotech News

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

T2 Biosystems (TTOO)T2 BiosystemsPartnership

Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream LEXINGTON, Mass. , Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of

Related news

BIAFbioAffinity Technologies, Inc.2026-04-28 13:16 EST

bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment

BJDXBluejay Diagnostics2026-09-08 10:30 EST

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

BJDXBluejay Diagnostics2026-06-02 10:30 EST

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

BIAFbioAffinity Technologies, Inc.2026-09-30 12:00 EST

bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL

DGXQuest Diagnostics2026-03-12 20:07 EST

Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors

INBSIntelligent Bio Solutions2026-02-25 13:45 EST

Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry

LUCDLucid Diagnostics2026-08-05 12:46 EST

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

DGXQuest Diagnostics2026-06-18 12:57 EST

UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics

OSUROraSure Technologies, Inc.2026-04-17 00:10 EST

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

View all latest news

T2 Biosystems

T2 Biosystems is a medical diagnostics company focused on rapid pathogen detection and bloodstream infection testing. Its business is centered on delivering fast diagnostic information to clinical settings.

Recent company news

TTOOT2 Biosystems2025-01-07 14:00 EST

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

TTOOT2 Biosystems2024-12-18 14:00 EST

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

TTOOT2 Biosystems2024-12-17 14:00 EST

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

TTOOT2 Biosystems2024-12-16 14:00 EST

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

TTOOT2 Biosystems2024-12-09 14:00 EST

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

Stock data

Close
0.00 USD
Market cap
—
Exchange
NASDAQ
Sector
MedTech
Location
United States